NEBULA

🚀 WE ARE NAMED AMONG THE TOP 100 SCIENCE STARTUPS TO WATCH IN 2026 We are thrilled to announce that NEBULA has been selected for the Falling Walls Venture Shortlist among the TOP 100 Science Startups to watch worldwide in 2026! Breaking the wall of undruggable therapeutic targets is at the heart of NEBULA's mission. By combining AI with structural biology, we're opening new therapeutic possibilities for diseases that have long remained beyond the reach of conventional drug discovery. Congratulations to all the inspiring ventures on this year's shortlist. We're excited to help shape the future of science and innovation together.

🚀 WE ARE NAMED AMONG THE TOP 100 SCIENCE STARTUPS TO WATCH IN 2026 We are thrilled to announce that NEBULA has been selected for the Falling Walls Venture Shortlist among the TOP 100 Science Startups to watch worldwide in 2026! Breaking the wall of undruggable therapeutic targets is at the heart of NEBULA's mission. By combining AI with structural biology, we're opening new therapeutic possibilities for diseases that have long remained beyond the reach of conventional drug discovery. Congratulations to all the inspiring ventures on this year's shortlist. We're excited to help shape the future of science and innovation together.

[RECHERCHE]🚀 Une nouvelle reconnaissance pour l'innovation issue de la recherche lorraine ! 🚀 La start-up NEBULA, accompagnée par l'Incubateur Lorrain, fait partie des 28 nouveaux lauréats de l'appel à projets « Pionniers de l'IA », un dispositif national de France 2030 visant à soutenir les projets de R&D en intelligence artificielle à fort impact pour l'économie et la souveraineté nationale. 💊 Créée à partir d'innovations développées au sein du Laboratoire de Physique et Chimie Théoriques (LPCT), Nebula met l'intelligence artificielle au service de la découverte de nouveaux médicaments. 🎯 Sa technologie permet d'explorer les différentes conformations des cibles thérapeutiques afin d'accélérer le développement de traitements innovants. Dans le cadre de ce projet, Nebula s'appuie également sur un partenariat avec le Laboratoire de Génie Informatique, de Production et de Maintenance (#LGIPM) pour développer une approche de co-conception IA-matériel, ouvrant de nouvelles perspectives pour l'industrialisation de cette innovation. ✨ Cette distinction marque une nouvelle étape dans le développement de la jeune entreprise, déjà lauréate du concours i-Lab 2025, et illustre la capacité de notre écosystème à transformer les résultats de la recherche publique en innovations de rupture au service de la santé. 👏 Félicitations aux équipes de Nebula, aux chercheurs du LPCT et du LGIPM, ainsi qu'à l'ensemble des partenaires ayant contribué à cette réussite ! 👉 https://lnkd.in/e5GTPvRR   Daniel Wiczew Mounir TAREK Fabrice Balavoine CNRS Centre-Est  ANR (Agence nationale de la recherche) Cluster IA Grand Est ENACT #Innovation #IntelligenceArtificielle #France2030 

Everyone is racing to build bigger. We just won an award for betting on smaller. Today, NEBULA was named a laureate, a Pionnier, of France's national Pionniers de l'IA programme, unveiled at VivaTech. The thesis behind it cuts against everything the industry is shouting right now: The future of AI isn't more compute. It's more intelligence per euro. This is frugal AI. The project we were recognised for has one job: accelerate our own AI pipeline by three orders of magnitude. 1,000× faster. At a fraction of today's cost. Not 10% faster. Not twice as fast. A thousand times. We're not saying how yet. 😉 But the gap is about to become very visible. Thanks to Incubateur Lorrain Bpifrance BioValley France La French Tech France Biotech

🚀 Honored to present today NEBULA at the Start-up Pitch Session hosted by SAYENS and Incubateur Lorrain, in the iconic Hôtel de Ville, Place Stanislas in Nancy. At NEBULA, we leverage physics-driven generative AI to unlock what the industry still considers undruggable and to become a key enabler of next-generation drug discovery for pharma and biotech. Great to connect with investors and start-up founders:  Virginie MIATH, Grégory Givron, Yasmine Ben Hadj Gouider, Marc DERIVE, Grandemange Stephanie #NEBULA #DrugDiscovery #AI #TechBio

🚀 Big news for NEBULA Proud to announce that NEBULA has been selected for the Start-up Pitch Competition at #DeepTechAtelier2026 in Riga! 📅 May 14–15 📍 Riga, Latvia DeepTech Atelier is one of the leading deep tech events in Europe, bringing together startups, scientists, investors, and industry leaders to foster innovation and shape the future of technology. This is an exciting opportunity for us to showcase our vision, connect with key players, and contribute to this vibrant ecosystem. At NEBULA, we are driven by a bold ambition: making the “undruggable” druggable thanks to our physics-driven AI platform, unlocking new drug discovery possibilities to accelerate the development of transformative medicines. If you’re attending DeepTech Atelier, let’s connect! I’d love to exchange and explore future collaborations! #DeepTechAtelier #AI #DrugDiscovery #NEBULA 

🎤 NEBULA au Grand Oral des Trophées HealthTech de France Biotech Ravis d’avoir participé hier au PariSanté Campus dans la catégorie "Trophée Jeune Entreprise HealthTech". Un pitch de 3 minutes porté par Mounir Tarek (CEO), aux côtés de Fabrice Balavoine (COO), pour partager notre ambition : rendre l’undruggable druggable et faire émerger de nouvelles approches thérapeutiques à fort impact médical. 👏Bravo aux autres nominés Adcytherix (Jack Elands), TheraSonic (Benoit Larrat, PhD) et ZebraMed (Valerio Laghi, PhD) dans cette catégorie. #FranceBiotech #HealthTech #TechBio

This morning at Mines Paris - PSL, the momentum continued at the BioLabs Europe Investor Day 2026 with our second pitching session: bringing forward another wave of bold ideas and breakthrough science. A new group of founders took the stage, each pushing the boundaries of what’s possible in life sciences: 🔬 Jonathan Naccache — Brink Therapeutics 🔬 Sunidhi C Shetty, PhD — Invitris 🔬 María Teresa Pérez Zaballos — endogene.bio 🔬 Leif Erik Sander — Prevacta 🔬 Sahil Gupta — Future Therapeutics 🔬 Marine Moutia — One Biosciences 🔬 Mounir TAREK — NEBULA From novel therapeutics to enabling technologies, these startups reflect the diversity and ambition of today’s biotech ecosystem. Because once again, beyond the pitches: ✅ New connections were sparked, ✅ Ideas were challenged and refined, ✅ And the path from science to impact became a little clearer. This is what the BioLabs community is about: creating the space where innovation meets opportunity. Johannes Fruehauf | Johanna Michielin | Hélène Sire | Christophe Tallec | Maryline Meilland | Julie Barbier | Ann-Kristin Mueller | Ornella Mehlhorn | Max Pöhlmann | Garima Bhardwaj-Ohlendorf, Ph.D. | Sahar Davatgarbenam | Carol Austin | Gaelle COUTANT | Anne-Charlotte Riviere | Francois-Xavier Leroux | Meryem Jaatit| Susan Chase | John Freeman CPA, MST, CGMA |

Thrilled to have pitched NEBULA at BioLabs European Investor Day 2026 in Paris today! We were one of 6 startups selected to present to a room full of leading life science investors during European DeepTech Week. A huge thank you to BioLabs France for the opportunity and to all the investors who took the time to hear our vision. Making the undruggable, druggable. That's the mission.

🚀 NEBULA rejoint France Biotech. Une nouvelle étape pour accélérer notre ambition : rendre "l'undruggable druggable" et accélérer le développement de nouvelles thérapies à fort impact médical grâce à une IA fondée sur la physique. Heureux de contribuer à la dynamique de l’écosystème biotech français. #FranceBiotech #TechBio #IA #DrugDiscovery